Next Article in Journal
Untargeted Metabolomics Reveal Defensome-Related Metabolic Reprogramming in Sorghum bicolor against Infection by Burkholderia andropogonis
Previous Article in Journal
Brain Metabolomics Reveal the Antipyretic Effects of Jinxin Oral Liquid in Young Rats by Using Gas Chromatography–Mass Spectrometry
Article Menu

Export Article

Open AccessArticle
Metabolites 2019, 9(1), 7; https://doi.org/10.3390/metabo9010007

Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells

1
The Scripps Research Institute, Scripps Center for Metabolomics and Mass Spectrometry, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
2
Department of Food Chemistry and Toxicology, Faculty of Chemistry, University of Vienna, Währingerstraße 38, 1090 Vienna, Austria
3
Vienna Metabolomics Center (VIME), University of Vienna, 1090 Vienna, Austria
4
Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT 06511, USA
5
Oncology Research, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA
*
Author to whom correspondence should be addressed.
Received: 6 November 2018 / Revised: 19 December 2018 / Accepted: 21 December 2018 / Published: 2 January 2019
Full-Text   |   PDF [2636 KB, uploaded 2 January 2019]   |  

Abstract

The aims of this study were to determine whether combination chemotherapeutics exhibit a synergistic effect on breast cancer cell metabolism. Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6, and when patients are treated in combination with fulvestrant, an estrogen receptor antagonist, they have improved progression-free survival. The mechanisms for this survival advantage are not known. Therefore, we analyzed metabolic and transcriptomic changes in MCF-7 cells following single and combination chemotherapy to determine whether selective metabolic pathways are targeted during these different modes of treatment. Individually, the drugs caused metabolic disruption to the same metabolic pathways, however fulvestrant additionally attenuated the pentose phosphate pathway and the production of important coenzymes. A comprehensive effect was observed when the drugs were applied together, confirming the combinatory therapy’s synergism in the cell model. This study also highlights the power of merging high-dimensional datasets to unravel mechanisms involved in cancer metabolism and therapy. View Full-Text
Keywords: combination drug therapy; breast cancer; multi-omics; metabolomics; RNA-seq; XCMS Online combination drug therapy; breast cancer; multi-omics; metabolomics; RNA-seq; XCMS Online
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Warth, B.; Palermo, A.; Rattray, N.J.; Lee, N.V.; Zhu, Z.; Hoang, L.T.; Cai, Y.; Mazurek, A.; Dann, S.; VanArsdale, T.; Fantin, V.R.; Shields, D.; Siuzdak, G.; Johnson, C.H. Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells. Metabolites 2019, 9, 7.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top